Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results

Rhea-AI Summary

Apellis (Nasdaq: APLS) will host a conference call and webcast to discuss third quarter 2025 financial results on Thursday, October 30, 2025 at 8:30 a.m. ET.

Investors can pre-register to join by phone, and a live audio webcast plus slides will be available on the company’s Investors and Media "Events and Presentations" page. A replay of the webcast will be accessible for 90 days after the event.

Apellis describes itself as a global biopharmaceutical company focused on complement science with two C3-targeting medicines approved for four diseases; contact for investor inquiries is Eva Stroynowski at the company.

News Market Reaction – APLS

-4.24%

1 alert

-4.24% News Effect

On the day this news was published, APLS declined 4.24%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 F, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its third quarter 2025 financial results on Thursday, October 30, 2025, at 8:30 a.m. ET.

To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for 90 days following the event.

About Apellis 
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company leading the way in complement science to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two C3-targeting medicines approved to treat four serious diseases. Breakthroughs for patients include the first-ever therapy for geographic atrophy, a leading cause of blindness, and the first treatment for patients 12 and older with C3G or primary IC-MPGN, two severe, rare kidney diseases. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on LinkedIn and X.

Investor Contact:
Eva Stroynowski
eva.stroynowski@apellis.com
617.938.6229

FAQ

When will Apellis (APLS) discuss third quarter 2025 results?

Apellis will host the call on October 30, 2025 at 8:30 a.m. ET.

How can investors join the Apellis (APLS) Q3 2025 conference call?

Investors can pre-register for phone access or join the live audio webcast and slides on the company’s Investors and Media "Events and Presentations" page.

Will the Apellis (APLS) Q3 2025 webcast be available after the event?

Yes, a replay of the webcast will be available for 90 days following the event.

Where can I find the Apellis (APLS) event slides for the Q3 2025 call?

Slides will be posted on the company’s Investors and Media "Events and Presentations" page alongside the live webcast.

Who is the investor contact for Apellis (APLS) regarding the Q3 2025 call?

Investor inquiries can be directed to Eva Stroynowski at the provided email and phone number listed by the company.

What will Apellis (APLS) cover during the October 30, 2025 call?

The call will discuss the company’s third quarter 2025 financial results and related corporate updates.